Curcumin and tetrahydrocurcumin induce cell death in Ara-C-resistant acute myeloid leukemia.
Yu-Hsin TsengShyh-Shin ChiouJui-Pei WengPei-Chin LinPublished in: Phytotherapy research : PTR (2019)
Most anticancer agents induce cancer cell death; however, multidrug-resistant cancers often lead to treatment failure. The effective use of curcumin as an anticancer agent has been demonstrated in clinical trials. Tetrahydrocurcumin, a major curcumin metabolite, exhibits pharmacological activities similar to those of curcumin. Curcumin induces cell death mainly through the apoptosis pathway, and tetrahydrocurcumin induces cell death mainly via an autophagy pathway in HL60 cells. Here, we investigated whether curcumin and tetrahydrocurcumin can induce apoptosis- and autophagy-mediated cell deaths in Ara-C-resistant cancer cells, respectively. The results demonstrated that curcumin and tetrahydrocurcumin induced cell death by apoptosis and autophagy, respectively, in Ara-C-resistant HL60 cells. Thus, curcumin and tetrahydrocurcumin have potential applications in the treatment of acute myeloid leukemia with Ara-C resistance.
Keyphrases
- cell death
- cell cycle arrest
- acute myeloid leukemia
- multidrug resistant
- clinical trial
- induced apoptosis
- oxidative stress
- escherichia coli
- squamous cell carcinoma
- randomized controlled trial
- stem cells
- cell proliferation
- bone marrow
- cell therapy
- acinetobacter baumannii
- study protocol
- young adults
- signaling pathway
- pseudomonas aeruginosa
- diabetic rats
- combination therapy
- childhood cancer
- drug induced